136 related articles for article (PubMed ID: 27928738)
21. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
[TBL] [Abstract][Full Text] [Related]
23. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Funakoshi R; Tomoda Y; Kudo T; Furihata K; Kusuhara H; Ito K
Br J Clin Pharmacol; 2019 Jul; 85(7):1454-1463. PubMed ID: 30845361
[TBL] [Abstract][Full Text] [Related]
24. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.
Jenkins H; Sakurai Y; Nishimura A; Okamoto H; Hibberd M; Jenkins R; Yoneyama T; Ashida K; Ogama Y; Warrington S
Aliment Pharmacol Ther; 2015 Apr; 41(7):636-48. PubMed ID: 25707624
[TBL] [Abstract][Full Text] [Related]
25. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
26. Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans.
Kong WM; Sun BB; Wang ZJ; Zheng XK; Zhao KJ; Chen Y; Zhang JX; Liu PH; Zhu L; Xu RJ; Li P; Liu L; Liu XD
Acta Pharmacol Sin; 2020 Jun; 41(6):852-865. PubMed ID: 31969689
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.
Yee KL; Khalilieh SG; Sanchez RI; Liu R; Anderson MS; Manthos H; Judge T; Brejda J; Butterton JR
Clin Drug Investig; 2017 Jul; 37(7):659-667. PubMed ID: 28353169
[TBL] [Abstract][Full Text] [Related]
28. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Sarapa N; Britto MR; Mainka MB; Parivar K
Eur J Clin Pharmacol; 2005 Jun; 61(4):247-56. PubMed ID: 15887009
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
30. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
Vollmer T; Blight AR; Henney HR
Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
[TBL] [Abstract][Full Text] [Related]
31. Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Chen Y; Ogasawara K; Wood-Horrall R; Thomas M; Thomas M; He B; Liu L; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2022 Oct; 90(4):325-334. PubMed ID: 36001108
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
33. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
Boinpally R; Gad N; Gupta S; Periclou A
Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
[TBL] [Abstract][Full Text] [Related]
34. Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.
Wang YH; Schwartz JI; Luo WL; Jumes P; Desai R; Wenning LA; Wagner JA; Lai E
Cardiovasc Ther; 2011 Apr; 29(2):140-5. PubMed ID: 20337634
[TBL] [Abstract][Full Text] [Related]
35. Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects.
Astruc B; Jenkins H; Jenkins R
Clin Transl Sci; 2017 May; 10(3):208-216. PubMed ID: 28198590
[TBL] [Abstract][Full Text] [Related]
36. Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions.
Boetsch C; Parrott N; Fowler S; Poirier A; Hainzl D; Banken L; Martin-Facklam M; Hofmann C
Clin Pharmacokinet; 2016 Feb; 55(2):237-47. PubMed ID: 26341813
[TBL] [Abstract][Full Text] [Related]
37. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans.
Almeida L; Soares-da-Silva P
Drugs R D; 2003; 4(4):207-17. PubMed ID: 12848585
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan.
Mulford DJ; Leifke E; Hibberd M; Howden CW
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):278-284. PubMed ID: 34431240
[TBL] [Abstract][Full Text] [Related]
40. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
